IOL Chemicals and Pharmaceuticals Limited
All news and filings related to IOL Chemicals and Pharmaceuticals Limited.
View all news & filings- Medium impact
IOL Chemicals and Pharmaceuticals Limited Holds 39th AGM, Approves Financials and Director Reappointment
IOL Chemicals and Pharmaceuticals Limited conducted its 39th AGM on September 2, 2026. Key resolutions passed included adopting the FY26 financial statements and reappointing Mr. Kushal Kumar Rana as director. The remuneration of the Cost Auditor for FY27 was also ratified.
Read the summary - Low impact
IOL Chemicals Holds 39th AGM on Sept 2, 2026; All Resolutions Passed
IOL Chemicals and Pharmaceuticals Limited conducted its 39th AGM on September 2, 2026, via VC/OAVM. All ordinary resolutions, including the adoption of financial statements for FY26 and director re-appointment, were passed. The meeting concluded with 92 members attending, and voting results confirmed the majority approval of all resolutions.
Read the summary - Low impact
IOL Chemicals to meet Institutional Investors and Analysts on Sep 3, 2026
IOL Chemicals and Pharmaceuticals Limited will engage with institutional investors and analysts on September 3, 2026. The meeting, part of Phillip Capital's 'Market Marvel' event, will focus on past financial results and publicly available information. No UPSI will be disclosed.
Read the summary - High impact
IOL Chemicals Q1 FY27 Earnings Call Transcript Released; Revenue Up 37%
IOL Chemicals reported Q1 FY27 revenue of ₹756 crore, up 37% YoY. EBITDA grew 60.7% to ₹111 crore, and PAT increased by 89.9% to ₹64.5 crore. Non-ibuprofen products drove pharma growth, contributing 43% of revenue. The company expects 15-20% revenue growth and 14-15% EBITDA margins for FY27.
Read the summary - Low impact
IOLCP Submits Newspaper Publication on Special Window for Share Transfer
IOL Chemicals and Pharmaceuticals Limited has published notices regarding a special window for the transfer and dematerialisation of physical shares. This window is open from February 5, 2026, to February 4, 2027, to facilitate the process for eligible shareholders.
Read the summary - High impact
IOL Chemicals & Pharmaceuticals Q1 FY27 Investor Presentation Released
IOL Chemicals and Pharmaceuticals Limited reported Q1 FY27 revenue of ₹756.3 crore, up 37.1% YoY, with PAT at ₹64.5 crore, up 89.9% YoY. The company expects FY27 revenue growth of 15%-20% and EBITDA margins of 14%-15%. Key expansions include Paracetamol and Ethyl Acetate capacities. Exports are projected to contribute 25%-30% of revenue.
Read the summary - Low impact
IOL Chemicals Publishes Q1 FY27 Unaudited Financial Results
IOL Chemicals and Pharmaceuticals Limited published its un-audited financial results for the quarter ended 30th June 2026 on 11th August 2026. The results were featured in prominent newspapers as per SEBI regulations.
Read the summary - High impact
IOL Chemicals Q1 FY27 Revenue Surges 37.1% to ₹756.3 Cr, PAT Jumps 89.9%
IOL Chemicals reported record Q1 FY27 results with revenue up 37.1% to ₹756.3 crore and PAT up 89.9% to ₹64.5 crore. Pharmaceuticals revenue grew 43% YoY, driven by non-Ibuprofen APIs. Chemicals revenue increased 29% YoY. Exports contributed 28.5% of revenue. Clopidogrel API received NMPA approval in China.
Read the summary - High impact
IOLCP Q1FY27 Profit Rises to ₹64.48 Crore on 37% Revenue Growth
IOLCP reported Q1FY27 consolidated profit after tax of ₹64.40 crore, up from ₹33.93 crore in Q1FY26. Total income increased to ₹764.44 crore from ₹559.06 crore. Standalone profit after tax was ₹64.48 crore. Standalone revenue from operations stood at ₹756.26 crore.
Read the summary - Low impact
IOL Chemicals Announces 39th AGM on Sep 2, 2026, with E-voting Facility
IOL Chemicals and Pharmaceuticals Limited will hold its 39th Annual General Meeting on September 2, 2026, at 11:30 AM IST via video conference. The integrated annual report for FY26 has been dispatched. Remote e-voting is available from August 30 to September 1, 2026. The cut-off date for voting eligibility is August 26, 2026.
Read the summary - Low impact
IOL Chemicals to Host Q1 FY27 Earnings Call on August 13, 2026
IOL Chemicals and Pharmaceuticals Limited will hold an analyst/investor conference call on August 13, 2026, at 3:00 PM IST to discuss Q1 FY27 financial performance. Key management personnel will participate.
Read the summary - Low impact
IOL Chemicals Announces 39th AGM on September 2, 2026, via Video Conference
IOL Chemicals and Pharmaceuticals Limited will hold its 39th Annual General Meeting on September 2, 2026, via Video Conference. The agenda includes adopting FY26 financial statements and re-appointing director Mr. Kushal Kumar Rana. Remuneration for the Cost Auditor for FY27 will also be ratified.
Read the summary - Low impact
IOL Chemicals Announces 39th AGM on September 2, 2026, via Video Conference
IOL Chemicals and Pharmaceuticals Limited will hold its 39th AGM on September 2, 2026, at 11:30 AM IST. The meeting will be conducted via Video Conference (VC)/Other Audio Visual Means (OAVM). The AGM Notice and Annual Report for FY2025-26 will be dispatched electronically.
Read the summary - Medium impact
IOL Chemicals gets China NMPA nod for Clopidogrel Bisulfate API
IOL Chemicals and Pharmaceuticals Limited received approval from China's NMPA for its Clopidogrel Bisulfate API on July 14, 2026. This approval strengthens the company's regulatory portfolio and market access in China.
Read the summary - Low impact
IOLCP Announces Special Window for Physical Share Transfer & KYC Update Campaign
IOLCP announces a Special Window for physical share transfer-cum-dematerialisation for shares with transfer deeds executed before April 1, 2019. It also promotes the 'Saksham Niveshak' campaign (April 1 to July 9, 2026) for claiming unclaimed dividends and updating KYC. Contact Alankit Assignments Limited for details.
Read the summary - Low impact
IOL Chemicals & Pharma Intimates Shareholders on Unclaimed Dividend Communication
IOL Chemicals and Pharmaceuticals is notifying shareholders about unclaimed dividends. Communications are being sent to advise shareholders on claiming unpaid dividends and to update mandatory KYC details for physical shareholdings. Failure to claim or update details may result in transfer to the IEPF.
Read the summary - Low impact
IOL Chemicals: Minor Fire at Minoxidil Unit, Operations Temporarily Suspended
A minor fire occurred at IOLCP's Minoxidil manufacturing unit on June 9, 2026. No injuries were reported. Unit -9B operations will be suspended for 8-10 days. Other units are unaffected. The company expects no significant operational impact.
Read the summary - High impact
IOL Chemicals Q4 FY26: Revenue up 17.4% to ₹619 Cr, PAT surges 68% to ₹53 Cr
IOL Chemicals reported Q4 FY26 revenue of ₹619 Cr, up 17.4% YoY, and PAT surged 68% to ₹53 Cr. For FY26, revenue was ₹2,319 Cr (up 11.5%) and PAT ₹138 Cr (up 36%). The company plans a ₹1,200-1,400 Cr greenfield project over 4-5 years.
Read the summary - Low impact
IOL Chemicals to Meet Investors at 360 ONE Capital Conference on May 29
IOL Chemicals will attend the 360 ONE Capital Investor Conference on May 29, 2026, in Mumbai. Management will hold meetings to discuss past financial results and public information. No UPSI will be disclosed during the event.
Read the summary - Low impact
IOLCP: Audio Recording of Analysts/Investors Call for Q4 FY26 Results Available
IOL Chemicals and Pharmaceuticals Limited has released the audio recording of its Analysts/Investors Call for Q4 FY2026. The call, discussing the company's financial performance, took place on May 22, 2026. The recording is available online.
Read the summary - Medium impact
IOL Chemicals & Pharma: FY26 Investor Presentation - Revenue at ₹2,319.1 Cr, PAT at ₹137.7 Cr
IOLCP's Q4 FY26 standalone revenue rose 17.4% YoY to ₹619.5 crore, with PAT increasing 68.2% to ₹53.2 crore. FY26 revenue reached ₹2,319.1 crore, up 11.5% YoY, and PAT increased 36.4% to ₹137.7 crore. The company expanded Ethyl Acetate capacity to 1,20,000 MTPA and Acetic Anhydride to 32,000 MTPA. IOLCP aims for carbon neutrality by 2050, reducing Scope 1+2 emissions intensity by 8.8% in FY26.
Read the summary - Medium impact
IOL Chemicals Q4 FY26 Consolidated PAT at ₹20.58 Cr, Down 54%
IOL Chemicals reported Q4 FY26 consolidated PAT of ₹20.58 Cr, a 54% decrease from ₹44.90 Cr in Q4 FY25. Full-year consolidated PAT was ₹184.44 Cr, down from ₹195.65 Cr. Standalone PAT for Q4 FY26 was ₹27.55 Cr, down from ₹53.18 Cr. Board approved results on May 20, 2026.
Read the summary - High impact
IOLCP Q4 FY26 Revenue Surges 17.4% to ₹619.5 Cr, PAT Jumps 68.2%
IOL Chemicals and Pharmaceuticals Limited reported its Q4 FY26 results, achieving a record quarterly revenue of ₹619.5 crore, up 17.4% YoY. PAT surged 68.2% to ₹53.2 crore. For FY26, revenue was ₹2319.1 crore, with PAT at ₹137.7 crore. The company incurred ₹164 crore capex for expansion.
Read the summary - High impact
IOLCP Approves FY26 Audited Results, Plans New Triacetin Plant & Pantoprazole Capacity Expansion
IOLCP's Board approved FY26 audited results and declared an unmodified audit opinion. The 39th AGM is scheduled for September 2, 2026. The company will invest ₹16.88 crore for a new Triacetin plant (6000 MTPA) and ₹5.87 crore to enhance Pantoprazole capacity by 36 MTPA, both funded internally.
Read the summary - High impact
IOLCP Board Approves FY26 Audited Results, Greenlights Triacetin Plant & Pantoprazole Expansion
IOLCP's Board approved FY26 audited standalone and consolidated financial results. The 39th AGM is scheduled for September 2, 2026. The company will install a new "Triacetin" manufacturing plant with 6000 MTPA capacity, involving a ₹16.88 crore capex, and enhance "Pantoprazole" capacity by 36 MTPA with a ₹5.87 crore capex. Both projects are funded by internal accruals.
Read the summary - Medium impact
IOL Chemicals Announces Investor Conference Call on 22 May 2026 for Q4 FY26 Results
IOL Chemicals and Pharmaceuticals Limited will hold an investor conference call on 22 May 2026 at 3:00 PM IST to discuss the financial results for the quarter and year ended 31 March 2026. Key management participants include Mr. Pardeep Kumar Khanna (CFO) and Mr. Abhay Raj Singh (Sr. VP & Company Secretary).
Read the summary - Low impact
IOL Chemicals Clarifies Volume Movement, No Pending Price-Sensitive Information
IOL Chemicals and Pharmaceuticals Limited clarified a recent surge in trading volume to the NSE. The company confirmed no pending price-sensitive information disclosures and reiterated its commitment to timely and transparent reporting as per SEBI regulations.
Read the summary - Medium impact
IOL Chemicals receives customs order imposing ₹2.06 crore fine
IOL Chemicals received an order from Customs, Kandla, imposing a total of ₹2.06 crore in differential duty, penalties, and fines. The charges relate to incorrectly availed ASEAN-India FTA exemptions. The company stated the levy will not materially impact its financials and plans to appeal the order.
Read the summary - Low impact
IOL Chemicals and Pharmaceuticals Limited Submits Compliance Certificate for SDD for Q4 FY26
IOL Chemicals and Pharmaceuticals Limited submitted its compliance certificate for the quarter ended March 31, 2026, regarding its Structured Digital Database (SDD). The company confirmed it has a compliant SDD in place, capturing all UPSI and maintaining an audit trail for eight years.
Read the summary - Low impact
IOL Chemicals Publishes Newspaper Advertisement for Special Securities Transfer Window
IOL Chemicals and Pharmaceuticals Limited published a newspaper advertisement on April 11, 2026, regarding a special window for the transfer and dematerialisation of physical securities. The advertisement appeared in the Financial Express and Punjabi Jagran.
Read the summary - Low impact
IOL Chemicals Relaunches 'Saksham Niveshak' Campaign for Unclaimed Dividends
IOL Chemicals relaunches "Saksham Niveshak" campaign from April 1 to July 9, 2026, to help shareholders claim unpaid dividends and update KYC details. The initiative aims to prevent unclaimed dividends and shares from being transferred to the IEPF Authority.
Read the summary - Low impact
IOL Chemicals Joins 'Saksham Niveshak' Campaign to Facilitate Unclaimed Dividend Claims
IOL Chemicals has joined the 'Saksham Niveshak' campaign to help shareholders claim unpaid dividends from FY 2019-20 to FY 2025-26. Shareholders must update KYC details and submit required forms by July 9, 2026, to facilitate dividend claims and prevent transfer to IEPF. Physical shareholders contact RTA; Demat shareholders contact DP.
Read the summary - Low impact
IOL Chemicals Files SEBI Compliance Certificate for Q4 FY26
IOL Chemicals and Pharmaceuticals Limited submitted a compliance certificate for the quarter ended March 31, 2026. The certificate, received from Alankit Assignment Limited, confirms processing of dematerialized shares as per SEBI regulations.
Read the summary - Low impact
IOLCP's Subsidiary IOL Life Sciences Struck Off; No Material Financial Impact
Registrar of Companies approves striking off IOL Life Sciences Limited, a wholly owned subsidiary of IOL Chemicals and Pharmaceuticals Limited. The strike-off, effective April 1, 2026, has no material impact on IOLCP's financials or operations. The subsidiary reported nil revenue and a net worth of ₹638,838/- as of March 31, 2025.
Read the summary - Low impact
IOL Chemicals: Trading Window Closed for Q4FY26 Results from April 1st
IOL Chemicals and Pharmaceuticals Limited (IOLCP) will close its trading window from April 1st, 2026. The window will reopen 48 hours after the declaration of audited financial results for the quarter and year ended March 31st, 2026. The board meeting date for approving results will be announced later.
Read the summary - Low impact
NCVI Enterprises Limited, Promoter Group, Buys 4.04 Lakh Shares of IOLCP
NCVI Enterprises Limited, a promoter group entity, purchased 4,04,305 equity shares of IOL Chemicals and Pharmaceuticals Limited on March 19, 2026. This increases their total holding to 4,86,55,000 shares, representing 16.58% of the company's equity.
Read the summary - Low impact
IOL Chemicals Promoter Group Entity NCVI Enterprises Buys 7 Lakh Shares
NCVI Enterprises Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited (IOLCP), acquired 7,00,000 equity shares on March 18, 2026. This increased their total shareholding to 5,14,08,739 shares, representing 16.44% of the company's equity. The disclosure was made under SEBI's insider trading regulations.
Read the summary - Low impact
IOL Chemicals Promoter Group Entity Mayadevi Polycot Limited Discloses Shareholding Changes
Maya devi Polycot Limited, a promoter group entity of IOLCP, sold 54,197 equity shares on March 18, 2026. Their shareholding decreased from 21.78% to 21.76%. The disclosure was made on March 19, 2026.
Read the summary - Low impact
IOL Chemicals Promoter Group Entity Buys 6.54 Lakh Shares
Maya Devi Polycot Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited, acquired 6,54,123 equity shares on March 17, 2026. Following the purchase, their holding increased to 6,38,91,133 shares, representing 21.76% of the company's equity.
Read the summary - Low impact
IOL Chemicals Promoter NCVI Enterprises Buys 7 Lakh Shares
NCVI Enterprises Limited, a promoter group entity of IOL Chemicals and Pharmaceuticals Limited, acquired 7,00,000 equity shares on March 16, 2026. This transaction increased their shareholding from 15.96% to 16.20%. The disclosure was made on March 18, 2026.
Read the summary - Low impact
IOLCP Clarifies Financial Results Format, Cites Compliance with Indian Accounting Standards
IOLCP clarified its Q3 FY26 financial results format, assuring compliance with Indian Accounting Standards and Schedule III of the Companies Act, 2013. The company explained that similar standalone and consolidated figures are due to subsidiaries not yet operational, leading to minor differences in profit and expenses.
Read the summary - Medium impact
IOLCP receives EDQM CEP Certificate for Metformin Hydrochloride Process-II
IOL Chemicals and Pharmaceuticals Limited (IOLCP) received a Certificate of Suitability (CEP) from EDQM for its "METFORMIN HYDROCHLORIDE Process -II" API product on March 5, 2026. This enhances their existing CEP for Metformin Hydrochloride, a key antidiabetic drug.
Read the summary - Medium impact
IOL Chemicals Expands Ethyl Acetate and Acetic Anhydride Capacity by ₹9.71 Crore
IOL Chemicals and Pharmaceuticals Limited has expanded Ethyl Acetate capacity by 20,000 MTPA to 1,20,000 MTPA with a ₹4 crore capex. Acetic Anhydride capacity increased by 7,000 MTPA to 32,000 MTPA with a ₹5.71 crore capex. Both expansions were funded by internal accruals and completed on March 2, 2026.
Read the summary - Medium impact
IOLCP receives EDQM CEP Certificate for Clopidogrel Besilate
IOL Chemicals and Pharmaceuticals Limited announced on February 24, 2026, that it received a Certificate of Suitability (CEP) from EDQM for its API product, Clopidogrel Besilate, on February 23, 2026. This is in addition to an existing CEP for Clopidogrel Bisulphate. Clopidogrel is an antiplatelet medication.
Read the summary - Low impact
IOLCP Announces Special Window for Dematerialisation of Physical Securities
IOLCP opens a Special Window from February 5, 2026, to February 4, 2027, for dematerialisation of physical securities. This applies to shares with transfer deeds executed before April 1, 2019. Processed shares will have a one-year lock-in period.
Read the summary - Medium impact
IOLCP Q3 FY26 Earnings Call Transcript Released: Revenue Up 10.9%, PAT Guidance for Q4
IOLCP reported Q3 FY26 revenue of ₹580 crore, up 10.9% YoY, with EBITDA at ₹62.6 crore, up 22.8%. For 9MFY26, revenue was ₹1,699.6 crore, up 9.6%. The company declared an interim dividend of 50%. Management expects 10-15% revenue growth and 15-20% profit growth in FY27. Q4 FY26 revenue is projected at ₹600 crore.
Read the summary - Low impact
IOLCP Q3 & M9 FY26 Analyst Call Audio Recording Available
IOL Chemicals and Pharmaceuticals Limited has released the audio recording of its Q3 & M9 FY26 analyst and investor call, held on February 12, 2026. The recording is available via a provided link.
Read the summary - Low impact
IOL Chemicals Declares Interim Dividend of ₹1; Sets Feb 17 as Record Date
IOL Chemicals declared an interim dividend of ₹1 per share for FY 2025-26. The record date is February 17, 2026. TDS rules apply, with a ₹10,000 threshold for no deduction for resident individuals. Declarations for intermediaries are due by February 17, 2026.
Read the summary - Medium impact
IOL Chemicals Announces Interim Dividend of ₹1/Share; Record Date Feb 17
IOL Chemicals and Pharmaceuticals Limited has declared an interim dividend of ₹1 per share for FY 2025-26. The record date for this dividend is February 17, 2026. The company will deduct TDS as per income tax regulations.
Read the summary - Medium impact
IOLCP Declares ₹1 Interim Dividend; Q3 FY26 Results Announced
IOL Chemicals and Pharmaceuticals Limited announced its Q3 FY26 results with total income at ₹585.68 crore and net profit after tax at ₹20.58 crore. For the nine months ended Dec 31, 2025, income was ₹1719.15 crore and net profit after tax was ₹84.54 crore. The company declared an interim dividend of ₹1 per share, with a record date of February 17, 2026.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio